Eikon Therapeutics, Inc. EIKN
6.00 USD +0.10 (+1.69%)
Nov 9, 2026, 9:40 AM EST
5.93 Day range 6.03
5.01 52-week range 17.40
- YTD
- -60.00%
- 1 year
- -60.00%
- Market cap
- 323.64M
- EPS (ttm)
- -8.51
- YTD return
- -60.00%
- 1-year return
- -60.00%
- Volume
- 5.96K
- Avg volume
- 575.06K
- Open
- 6.03
- Previous close
- 5.90
- Day's range
- 5.93 – 6.03
- 52-week range
- 5.01 – 17.40
5D +0.55 (+10.28%)
Financials — quick view
EIKN Revenue — quarterly 0
EIKN Net income — quarterly -88.41M
EIKN EPS — quarterly -1.63
News
Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029 
Eikon Therapeutics to Participate in Multiple Investor Conferences in November 
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting 
Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile 
HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23 
Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer 
Alpha Buying: Follow the Money From NVIDIA and Merck 
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday 
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4
Your note
Sign in to keep a note on EIKN — it syncs with the Stock Master app.